Meet the 12 startups in IndieBio’s SF Cohort, and discover what about each swayed investors – TechCrunch
It’s been a big two years for biotech investors. But if you ask Po Bronson, a partner at SOSV’s IndieBio, this trend was probably a long time coming. “Often, the implication is that everything must be overpriced,” he tells TechCrunch. “But I think more of it is that some major theses in the markets are…